Ivelin Georgiev

(Adobe Stock)
January 16, 2026

Vanderbilt Health team finds potent antibody that neutralizes two dangerous viruses

The single administration of an antibody that provides cross-protection against both RSV and hMPV infection could provide logistical and economic advantages over the need to develop and administer multiple virus-specific monoclonal antibodies.

By Bill Snyder
Cryogenic electron microscopy (cryo-EM) resolution of the structure of a respiratory syncytial virus fusion protein (shades of pink) bound to fragments of two antibodies (dark/light and blue/green) designed by the researchers’ protein language model, MAGE.
November 4, 2025

AI can speed antibody design to thwart novel viruses: study

While the study focused on development of antibody therapeutics against existing and emerging viral threats, the implications of the research are much broader.

By Bill Snyder
March 10, 2025

VUMC to develop AI technology for therapeutic antibody discovery

The approach will address “bottlenecks” that slow the traditional antibody discovery process, and it aims to make it possible to generate monoclonal antibody therapies against any target of interest.

By Leigh MacMillan
September 20, 2024

VUMC method tracks down rare, broadly reacting antibodies: study

The discovery, reported in the journal PLOS Pathogens, could help open the door to the development of effective vaccines and antibody therapies with an “exceptional breadth of pathogen coverage.”

By Bill Snyder
March 28, 2024

VUMC team discovers antibodies that may prevent severe respiratory illness

Using a technique developed at Vanderbilt University Medical Center, researchers identified antibodies that are excellent leads as potential therapies for human parainfluenza virus 3, a leading cause of acute and potentially fatal respiratory illness.

By Bill Snyder
November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

By Bill Snyder
February 2, 2023

Discovery of “cross-reactive” antibodies could aid treatment of viral co-infections

By Bill Snyder
January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.
By Bill Snyder
July 20, 2022

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.
By Leigh MacMillan
March 24, 2022

Grant set to support Georgiev’s research to identify new antibodies

Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.
By Bill Snyder
March 10, 2022

Technique hastens COVID-19 antibody discovery

Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
By Bill Snyder
October 29, 2020

Grant helps expand VI4’s Artist-in-Residence program

An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.
By Leigh MacMillan